141 related articles for article (PubMed ID: 32535103)
1. Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1.
Feng Q; Li X; Sun W; Sun M; Li Z; Sheng H; Xie F; Zhang S; Shan C
Biochem Pharmacol; 2020 Aug; 178():114092. PubMed ID: 32535103
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of STAT3 reverses Taxol-resistance in ovarian cancer by down-regulating G6PD expression in vitro.
Sheng H; Feng Q; Quan Q; Sheng X; Zhang P
Biochem Biophys Res Commun; 2022 Aug; 617(Pt 2):62-68. PubMed ID: 35689843
[TBL] [Abstract][Full Text] [Related]
3. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
4. A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer.
Byun WS; Jin M; Yu J; Kim WK; Song J; Chung HJ; Jeong LS; Lee SK
Biochem Pharmacol; 2018 Dec; 158():84-94. PubMed ID: 30292755
[TBL] [Abstract][Full Text] [Related]
5. Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation.
Mele L; la Noce M; Paino F; Regad T; Wagner S; Liccardo D; Papaccio G; Lombardi A; Caraglia M; Tirino V; Desiderio V; Papaccio F
J Exp Clin Cancer Res; 2019 Apr; 38(1):160. PubMed ID: 30987650
[TBL] [Abstract][Full Text] [Related]
6. Glutathione S-transferases P1-mediated interleukin-6 in tumor-associated macrophages augments drug-resistance in MCF-7 breast cancer.
Dong X; Sun R; Wang J; Yu S; Cui J; Guo Z; Pan X; Sun J; Yang J; Pan LL
Biochem Pharmacol; 2020 Dec; 182():114289. PubMed ID: 33080187
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
8. Glucose-6-phosphate dehydrogenase: a therapeutic target for ovarian cancer.
Wang C; Yu C; Chang H; Song J; Zhang S; Zhao J; Wang J; Wang T; Qi Q; Shan C
Expert Opin Ther Targets; 2023; 27(8):733-743. PubMed ID: 37571851
[TBL] [Abstract][Full Text] [Related]
9. Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.
Min HY; Lee HJ; Suh YA; Pei H; Kwon H; Jang HJ; Yun HJ; Moon HG; Lee HY
Br J Cancer; 2022 Sep; 127(4):661-674. PubMed ID: 35597872
[TBL] [Abstract][Full Text] [Related]
10. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
11. ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.
Feng J; Peng Z; Gao L; Yang X; Sun Z; Hou X; Li E; Zhu L; Yang H
Biomed Pharmacother; 2021 Jun; 138():111407. PubMed ID: 33765585
[TBL] [Abstract][Full Text] [Related]
12. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
Huang SL; Chang TC; Chao CCK; Sun NK
Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
[TBL] [Abstract][Full Text] [Related]
13. A GSTP1-mediated lactic acid signaling promotes tumorigenesis through the PPP oxidative branch.
Sun Y; He Q; Li J; Yang Z; Ahmad M; Lin Y; Wu D; Zheng L; Li J; Wang B; Chen C; Hu Y; Luo H; Luo Y
Cell Death Dis; 2023 Jul; 14(7):463. PubMed ID: 37491277
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
[TBL] [Abstract][Full Text] [Related]
15. CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.
Tang XH; Li H; Zheng XS; Lu MS; An Y; Zhang XL
Cancer Med; 2019 Oct; 8(14):6426-6436. PubMed ID: 31490008
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
Xu Y; Zhang J; Wu J; Zhong S; Li H
Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death.
Catanzaro D; Gaude E; Orso G; Giordano C; Guzzo G; Rasola A; Ragazzi E; Caparrotta L; Frezza C; Montopoli M
Oncotarget; 2015 Oct; 6(30):30102-14. PubMed ID: 26337086
[TBL] [Abstract][Full Text] [Related]
18. TKTL1 modulates the response of paclitaxel-resistant human ovarian cancer cells to paclitaxel.
Zheng X; Li H
Biochem Biophys Res Commun; 2018 Sep; 503(2):572-579. PubMed ID: 29885837
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
20. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
